Chiesi Group announced the completion of its acquisition of KalVista Pharmaceuticals, adding the rare disease specialist to its organization and expanding the capabilities of its Global Rare Diseases business unit.
As part of the transaction, KalVista becomes a wholly owned subsidiary of Chiesi and its common stock has ceased trading on the Nasdaq Global Market.
The acquisition gives Chiesi ownership of EKTERLY (sebetralstat), the first and only oral, on-demand treatment for hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older. The therapy has already received approvals in the United States, United Kingdom, European Union, Japan, and several other markets. Additional studies are underway to evaluate the treatment in children ages 2 to 11, while regulatory applications remain under review in multiple countries.
Chiesi completed its tender offer on June 11, 2026, purchasing all validly tendered shares at $27 per share in cash. Approximately 77.8% of KalVista’s outstanding shares were tendered. Following the completion of the tender offer, Chiesi finalized the acquisition through a merger involving a wholly owned subsidiary, resulting in the cancellation of the remaining shares and their conversion into the right to receive the same cash consideration.
KalVista is known for discovering and developing sebetralstat and has focused on delivering oral therapies for patients affected by rare diseases with significant unmet medical needs.
Chiesi said KalVista will contribute to the continued expansion of its Rare Diseases business, which focuses on the research, development, and commercialization of therapies for rare and ultra-rare conditions.
Founded in Italy, Chiesi is a research-focused international biopharmaceutical group operating in respiratory health, rare diseases, and specialty care. The company employs more than 7,900 people globally and maintains research and development hubs across Europe, North America, and Asia.
Support: Advising Chiesi on the transaction were Lazard and Ropes & Gray LLP, while Centerview Partners, Kirkland & Ellis LLP, and Fenwick & West LLP advised KalVista.
